‘Serious Risks to Women’: Over 20 Attorneys General Call for Regulation of Abortion Pill

‘[I]n the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.